

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5



Figure 6

Blood pressure-lowering  
effect by drug administration




Figure 7

Urinary protein inhibiting  
effect by drug administration




Figure 8

Thy-1 Nephritis model




Figure 9

Thy-1 Nephritis model




Figure 10

Thy-1 Nephritis model




Figure 11




Figure 12

Ischemia-reperfusion model




Figure 13

ischemia-reperfusion model





Figure 14








Figure 16

Stability of TM-2002 injectable lyophilized formulation




1. TM-2002 injectable lyophilized formulation-aqueous solution (1ml) diluted with saline (1.5 ml)
2. TM-2002 hydrochloride  
(material: prepared when used for TLC)
3. TM-2002 hydrochloride (material) aqueous solution


Figure 17




ORP 150 immunostaining in WKY drug free group



ORP 150 immunostaining in SHR drug free group



ORP 150 immunostaining in SHR/NDmcrcp drug free group



ORP 150 immunostaining in SHR/NDmcrcp TM-2002 administered group

Figure 18




Figure 19

